Yellow Fever

🦠 What Is Yellow Fever?

Yellow Fever is a serious viral hemorrhagic fever caused by the yellow fever virus, a member of the Flavivirus genus. This acute infectious disease primarily targets the liver, kidneys, and heart, and can lead to severe jaundice—the characteristic yellowing of the skin and eyes that gives the disease its name. The virus is classified as an arbovirus (arthropod-borne virus) and is maintained in nature through a sylvatic cycle involving non-human primates and specific mosquito vectors.

The disease has historically been one of the most feared tropical infections, responsible for devastating epidemics that shaped global trade and colonization patterns. Today, it remains a significant public health concern in endemic regions. The incubation period typically ranges from 3 to 6 days after the bite of an infected mosquito. While many infections are mild or asymptomatic, approximately 15% of cases progress to a severe, toxic phase with a case fatality rate of 20–50% in hospitalized patients.

🔄 How It Spreads

Yellow Fever transmission occurs exclusively through the bite of infected female mosquitoes, primarily of the Aedes and Haemagogus genera. The virus replicates in the mosquito's salivary glands and is transmitted to humans during a blood meal. Importantly, there is no direct human-to-human transmission.

Three distinct transmission cycles exist:

• Sylvatic (Jungle) Cycle: The virus circulates between non-human primates (monkeys) and canopy-dwelling mosquitoes. Humans become infected incidentally when entering forested areas.
• Intermediate (Savannah) Cycle: Occurs in humid or semi-humid regions of Africa, involving both primates and humans as hosts, with mosquito species breeding near human habitations.
• Urban Cycle: Involves Aedes aegypti mosquitoes densely populated urban environments, leading to explosive epidemics with rapid human-to-human transmission via mosquitoes.

⚠️ Symptoms & Disease Progression

The disease progresses in distinct phases, with a period of remission between the initial and toxic phases:

Initial Phase (3–6 days post-infection):

• Sudden onset of fever, often >39°C (102.2°F)
• Chills and severe headache
• Myalgia, particularly back pain
• Nausea, vomiting
• Bradycardia (Faget's sign)

Remission Phase (24–48 hours):

• Fever subsides; patient may feel better
• Some cases resolve completely

Toxic Phase (15% of cases):

• High fever returns
• Jaundice (liver damage)
• Hemorrhagic manifestations: hematemesis ("black vomit"), melena, petechiae, ecchymoses
• Renal failure with oliguria or anuria
• Delirium, seizures, coma
• Multi-organ failure

🌍 Global Distribution & Epidemiology

Yellow Fever is endemic in tropical regions of Africa and South America. The World Health Organization estimates 200,000 cases annually, with 30,000 deaths, 90% occurring in Africa. Major outbreaks have occurred in Angola, Democratic Republic of Congo, Brazil, and Peru.

Urban Yellow Fever remains a constant threat due to high Aedes aegypti density in cities. Climate change and urbanization expand potential transmission zones. The International Health Regulations require proof of vaccination for travel to endemic areas.

🔬 Diagnosis

Diagnosis is challenging due to symptom overlap with other viral hemorrhagic fevers. Serological tests detect IgM antibodies via ELISA, but cross-reactivity with other flaviviruses complicates interpretation. RT-PCR detects viral RNA in blood during acute phase. Liver biopsy is contraindicated due to hemorrhage risk.

Differential diagnosis includes dengue, malaria, leptospirosis, viral hepatitis, and other hemorrhagic fevers. Plaque reduction neutralization test (PRNT) provides definitive confirmation.

💊 Treatment & Prevention

No antiviral therapy exists. Treatment is supportive care: fluid management, heparin for DIC, dialysis for renal failure. Aspirin is contraindicated.

Prevention relies on vaccination with the 17D vaccine, a live attenuated vaccine providing lifelong immunity in 99% of recipients. A single dose confers immunity within 30 days. Vector control includes insecticide-treated nets and larviciding. Travelers must present International Certificate of Vaccination for entry to endemic countries.

📊 High-Risk Groups

• Unvaccinated travelers to endemic areas
• Outdoor workers in forested regions
• Immunocompromised individuals with potential vaccine contraindications
• Elderly individuals with higher case fatality rates
• Urban populations with high Aedes aegypti density
• Individuals with thymus disorders or egg allergies (vaccine contraindications)